Confluence Investment Management LLC Cuts Position in Medtronic PLC $MDT

Confluence Investment Management LLC lowered its position in Medtronic PLC (NYSE:MDT) by 10.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 174,010 shares of the medical technology company’s stock after selling 21,230 shares during the quarter. Confluence Investment Management LLC’s holdings in Medtronic were worth $15,015,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Monetary Solutions Ltd bought a new stake in Medtronic in the fourth quarter worth about $27,000. IAG Wealth Partners LLC bought a new position in shares of Medtronic during the second quarter valued at approximately $30,000. Pin Oak Investment Advisors Inc. purchased a new stake in shares of Medtronic in the second quarter worth approximately $32,000. Community Bank N.A. purchased a new stake in shares of Medtronic in the second quarter worth approximately $33,000. Finally, Core Capital Management & Research inc. bought a new stake in shares of Medtronic during the 2nd quarter worth approximately $33,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.4%

Shares of Medtronic stock traded down $0.31 during trading on Thursday, hitting $85.98. 13,134,591 shares of the stock traded hands, compared to its average volume of 9,199,728. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The stock’s fifty day simple moving average is $90.00 and its 200 day simple moving average is $84.78. The firm has a market cap of $109.98 billion, a P/E ratio of 21.16, a price-to-earnings-growth ratio of 1.98 and a beta of 0.56. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts predict that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is presently 70.94%.

Wall Street Analysts Forecast Growth

MDT has been the topic of several research analyst reports. Robert W. Baird upped their price objective on Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research report on Wednesday, September 2nd. Jefferies Financial Group reissued a “hold” rating and set a $88.00 target price on shares of Medtronic in a research note on Thursday, June 4th. The Goldman Sachs Group cut their price target on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. UBS Group raised their price target on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Finally, Truist Financial reissued a “hold” rating and issued a $99.00 price objective (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Nineteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $103.92.

Insider Transactions at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.27% of the stock is currently owned by insiders.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic announced FDA clearance and CE Mark milestones for its Affera Prism-2 Mapping Software, along with CE Mark approval for the PulseSelect ProxBox Adapter. The approvals expand the company’s cardiac ablation and mapping capabilities and could support adoption of its electrophysiology portfolio. Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
• Positive Sentiment: The FDA cleared Medtronic’s LigaSure RAS Maryland jaw for use with its Hugo robotic-assisted surgery system in the United States. The device broadens Hugo’s instrument lineup and may make the platform more attractive to hospitals evaluating robotic surgery systems. Medtronic receives FDA clearance for LigaSure RAS device
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating and assigned a $110 price target, implying substantial upside from recent trading levels. The endorsement supports the view that Medtronic’s valuation and product pipeline remain attractive. TD Cowen rating update
• Neutral Sentiment: Commentary from Motley Fool and Zacks describes Medtronic as a potentially attractive long-term value stock, citing its valuation, financial profile and strategy. These opinions may support investor interest but do not represent new company-specific catalysts.
• Neutral Sentiment: Medtronic’s William J. Peine was named the 2026 Inventor of the Year for patented innovations related to the Hugo robotic-assisted surgery system. The recognition highlights research strength but has limited immediate earnings impact. IPO Education Foundation names Medtronic inventor of the year
• Negative Sentiment: Put-option volume rose about 45% above its average, indicating increased bearish speculation or downside hedging. This options activity may be contributing to short-term weakness, although it does not by itself confirm a fundamental deterioration.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.